Vestmark Advisory Solutions Inc. Has $5.14 Million Position in Intellia Therapeutics, Inc. $NTLA

Vestmark Advisory Solutions Inc. trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 53.4% in the third quarter, Holdings Channel.com reports. The firm owned 297,566 shares of the company’s stock after selling 340,776 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Intellia Therapeutics were worth $5,139,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Blue Bell Private Wealth Management LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter valued at about $30,000. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics in the 2nd quarter valued at about $26,000. Federated Hermes Inc. increased its holdings in shares of Intellia Therapeutics by 39.7% during the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock valued at $56,000 after acquiring an additional 927 shares in the last quarter. Whipplewood Advisors LLC raised its position in shares of Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after purchasing an additional 3,447 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Intellia Therapeutics in the 2nd quarter valued at $52,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Buying and Selling at Intellia Therapeutics

In related news, EVP Birgit C. Schultes sold 8,508 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP James Basta sold 10,397 shares of Intellia Therapeutics stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at approximately $935,072.88. This trade represents a 9.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 53,051 shares of company stock worth $488,600. Company insiders own 3.10% of the company’s stock.

Intellia Therapeutics Stock Down 3.1%

Shares of NTLA opened at $12.64 on Monday. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25. The firm has a 50 day moving average of $11.43 and a 200 day moving average of $12.95. The company has a market capitalization of $1.46 billion, a P/E ratio of -2.96 and a beta of 2.10.

Analysts Set New Price Targets

A number of research analysts have weighed in on NTLA shares. Wells Fargo & Company dropped their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Evercore set a $8.00 target price on Intellia Therapeutics and gave the company an “in-line” rating in a research note on Tuesday, November 11th. JonesTrading lowered Intellia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. restated an “underweight” rating and set a $5.00 price target (down previously from $12.00) on shares of Intellia Therapeutics in a research report on Friday, November 7th. Finally, Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, October 27th. Eight research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $17.48.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.